ArticleCancer research2019
CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 63 citations in OpenAlex.
- Reprogramming resistance in advanced lung cancer: epigenetic modulation to restore therapeutic vulnerability.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Targeting cytokine/chemokine signaling to convert immunologically cold tumors into hot: Emerging strategies in cancer immunotherapy.Acta pharmaceutica Sinica. B · 2026Review
- Atlas-Guided Nanocarrier Strategies Targeting Spatial NTRK2/MAPK Signaling in EGFR-TKI-Resistant Niches of Esophageal Squamous Cell Carcinoma.Pharmaceutics · 2026Review
- The Activity of EGFR CAR NK and CAR T Cells against EGFR Inhibitor-Resistant NSCLC and Drug-Tolerant Persister Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Chaperone directed heterobifunctional molecules circumvent KRASCancer letters · 2025Article
- Hepatic Growth Factor as a Potential Biomarker for Lung Adenocarcinoma: A Multimodal Study.Current issues in molecular biology · 2025Article
- Macrophage Migration Inhibitory Factor (MIF) Upregulates CXCR7 and Contributes to Chemotherapy Resistance in Colorectal Cancer.Cell biochemistry and biophysics · 2024Article
- Genomic characteristics of PD-L1-Induced resistance to EGFR-TKIs in lung adenocarcinoma.Future oncology (London, England) · 2024Article
- The Impact of Inadequate Exposure to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors on the Development of Resistance in Non-Small-Cell Lung Cancer Cells.International journal of molecular sciences · 2024Article
- Prognostic Factors and Markers in Non-Small Cell Lung Cancer: Recent Progress and Future Challenges.Genes · 2023Review
- PHF23 promotes NSCLC proliferation, metastasis, and chemoresistance via stabilization of ACTN4 and activation of the ERK pathway.Cell death & disease · 2023Article
- Review
- The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention.Cellular & molecular immunology · 2023Review
- CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance.Cancer cell · 2023Article
- CXCL12-CXCR4/CXCR7 Axis in Cancer: from Mechanisms to Clinical Applications.International journal of biological sciences · 2023Review
- Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice.Frontiers in pharmacology · 2023Review
- CXCL14 promotes metastasis of non-small cell lung cancer through ACKR2-depended signaling pathway.International journal of biological sciences · 2023Article
- Article
- Germinal Center-Related G Protein-Coupled Receptors in Antibody-Mediated Autoimmune Skin Diseases: from Basic Research to Clinical Trials.Clinical reviews in allergy & immunology · 2022Review
- Atypical chemokine receptor 3 induces colorectal tumorigenesis in mice by promoting β-arrestin-NOLC1-fibrillarin-dependent rRNA biogenesis.Acta pharmacologica Sinica · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 12 institutions in 3 countries.
Jeffrey H BeckerDepartment of Surgery, Division of Cardiothoracic Surgery, University of Illinois at Chicago, Chicago, Illinois.
Yandi GaoDepartment of Molecular Pharmacology and Therapeutics, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois.
Margaret SoucherayDepartment of Molecular Pharmacology and Therapeutics, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois.
Ines PulidoDepartament de Fisiologia, Facultat de Farmacia, Universitat de València, Burjassot, Spain.
Eiki KikuchiFirst department of Medicine, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.
María L RodríguezDepartament de Fisiologia, Facultat de Farmacia, Universitat de València, Burjassot, Spain.
Rutu GandhiDepartment of Molecular Pharmacology and Therapeutics, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois.
Aranzazu Lafuente-SanchisDepartment of Molecular Biology, Hospital Universitario de la Ribera, Alzira, Valencia, Spain.
Miguel AupíDepartament de Fisiologia, Facultat de Farmacia, Universitat de València, Burjassot, Spain.ORCID 0000-0002-2252-5102
Javier Alcácer Fernández-CoronadoDepartment of Pathology, Hospital Quirónsalud Valencia, Valencia, Spain.
Paloma Martín-MartorellDepartment of Medical Oncology, Hospital Clínico Universitario de Valencia, Valencia, Spain.ORCID 0000-0002-6728-8366
Antonio CremadesDepartment of Pathology, Hospital Universitario de la Ribera, Alzira, Valencia, Spain.ORCID 0000-0003-0146-4475
José M Galbis-CaravajalDepartment of Thoracic Surgery, Hospital Universitario de la Ribera, Alzira, Valencia, Spain.
Javier AlcácerDepartment of Pathology, Hospital Quirónsalud Valencia, Valencia, Spain.
Camilla L ChristensenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Patricia SimmsDepartment of Molecular Pharmacology and Therapeutics, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois.ORCID 0000-0002-7257-9627
Ashley HessDepartment of Molecular Pharmacology and Therapeutics, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois.
Hajime AsahinaFirst department of Medicine, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.
Michael P KahleDepartment of Molecular Pharmacology and Therapeutics, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois.
Fatima Al-ShahrourBioinformatics Unit, Spanish National Cancer Research Centre, Madrid, Spain.ORCID 0000-0003-2373-769X
Jeffrey A BorgiaDepartment of Cell & Molecular Medicine, Rush University Medical Center, Chicago, Illinois.
Agustín LahozBiomarkers and Precision Medicine Unit, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
Amelia InsaDepartment of Medical Oncology, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Oscar JuanBiomarkers and Precision Medicine Unit, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.ORCID 0000-0002-7772-9030
Pasi A JänneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Kwok-Kin WongLaura and Isaac Perlmutter Cancer Center, Division of Hematology and Medical Oncology, New York University, New York, New York.
Julian CarreteroDepartament de Fisiologia, Facultat de Farmacia, Universitat de València, Burjassot, Spain. tshima2@uic.edu jcarrete@uv.es.
Takeshi ShimamuraDepartment of Surgery, Division of Cardiothoracic Surgery, University of Illinois at Chicago, Chicago, Illinois. tshima2@uic.edu jcarrete@uv.es.
Loyola University Chicago · USUniversitat de València · ESHospital de La Ribera · ESHokkaido University Hospital · JPHospital Clínico Universitario de Valencia · ESHospital Quirónsalud Barcelona · ESSpanish National Cancer Research Centre · ESDana-Farber Cancer Institute · USHospital Universitari i Politècnic La Fe · ESInstituto de Investigación Sanitaria La Fe · ESNYU Langone Health · USRush University Medical Center · US
Funding
StructureP01CA154303 · NCI · DANA-FARBER CANCER INST · PI MEYERSON, MATTHEW L. · 2012 to 2021
$17.8MMUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung CancerR01CA166480 · NCI · DANA-FARBER CANCER INST · PI KUFE, DONALD W., WONG, KWOK KIN · 2012 to 2021
$6.3MTherapeutic strategies for specific subsets of KRAS mutant lung cancersR01CA140594 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WONG, KWOK KIN · 2009 to 2017
$4.5MEGFR Mutations in Non-Small Cell Lung CancerR01CA114465 · NCI · DANA-FARBER CANCER INSTITUTE · PI JANNE, PASI A, JOHNSON, BRUCE E. · 2005 to 2016
$3.9MDrug Resistance in Lung CancerR01CA135257 · NCI · DANA-FARBER CANCER INST · PI JANNE, PASI A · 2008 to 2017
$3.5MIn vivo analysis of EGFR mutant driven lung cancers responses to radiation therapR01CA122794 · NCI · DANA-FARBER CANCER INST · PI WONG, KWOK KIN · 2006 to 2015
$2.8MIn vivo murine models of metastasis for therapeutic testingR01CA163896 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SHARPLESS, NORMAN E, WONG, KWOK KIN · 2012 to 2016
$2.0MInvestigation of CXCR7 signaling in EGFR TKI resistant NSCLCR01CA230778 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SHIMAMURA, TAKESHI · 2019 to 2023
$1.9MInvestigation and targeting of the transcriptional and epigenetic landscape of Small Cell Lung CancerK99CA201618 · NCI · DANA-FARBER CANCER INST · PI CHRISTENSEN, CAMILLA L · 2016 to 2017
$257kNCI NIH HHS K99 CA201618NCI NIH HHS P01 CA154303NCI NIH HHS R01 CA114465NCI NIH HHS R01 CA122794NCI NIH HHS R01 CA135257NCI NIH HHS R01 CA140594NCI NIH HHS R01 CA163896NCI NIH HHS R01 CA166480NCI NIH HHS R01 CA230778
Abstract
Although EGFR mutant-selective tyrosine kinase inhibitors (TKI) are clinically effective, acquired resistance can occur by reactivating ERK. We show using
Indexed as
Drug Resistance, NeoplasmAnimalsbeta-ArrestinsCarcinoma, Non-Small-Cell LungCell Line, TumorEpithelial-Mesenchymal TransitionErbB ReceptorsHumansLung NeoplasmsMAP Kinase Signaling SystemMice, TransgenicMutationNeoplasms, ExperimentalProtein Kinase InhibitorsReceptors, CXCRACKR3 protein, humanbeta-ArrestinsEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsReceptors, CXCR
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.